[This entry is marked for removal.]

Bayer HealthCare Pharmaceuticals Inc. (formerly Berlex Laboratories Inc) is the U.S.-based pharmaceuticals operation of Bayer HealthCare LLC, a division of Bayer AG.
Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the United States, Bayer HealthCare Pharmaceuticals is comprised of the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, Hematology/Neurology and Oncology.

See also Bayer Schering Pharma AG.

Berlex Laboratories has been integrated into Bayer HealthCare, and operates as an integrated specialty pharmaceuticals business under a new name, Bayer HealthCare Pharmaceuticals.
The company is developing and making specialized medicines for treating multiple sclerosis, dermatological disorders, female health concerns, cancer and is creating new diagnostic imaging techniques. Berlex Laboratories, Inc. was a pioneer in the imaging market. It introduced a broad range of imaging agents. Its contribution began in 1988 with the introduction of the world's first magnetic resonance imaging agent, Magnevist® (gadopentetate dimeglumine) injection. Berlex Laboratories, Inc. was an US affiliate of Bayer Schering Pharma AG Germany.

The company is a member of the Bracco Group, a highly innovative health care group and world leader in global integrated solutions for the diagnostic imaging field. The Bracco Group is headquartered in Milan, Italy. Its North American operations consist of Bracco Diagnostics and Bracco Research USA, both located in Princeton, New Jersey. Bracco Diagnostics is one of the fastest growing developers and marketers of diagnostic pharmaceuticals in North America, with products for various imaging applications, including Isovue® (iopamidol) X-ray contrast agent, ProHance®, (gadoteridol), MRI contrast agent, and nuclear medicine products.
Gadoteridol has been available in Europe and the USA for several years. Holder of the Marketing Authorization: Bracco International B.V. - Strawinskylaan 3051 - 1077 ZX Amsterdam The Netherlands. (Contact: Kirk Deeter, Phone: +NL-303-838-8708)

The Bracco Group is the world's leading provider of global diagnostic imaging solutions, with net sales of more than 1 billion euro, of which more than 64% from international sales; it has operations in 115 countries and about 3,500 employees, of whom more than 600 work in R&D. Bracco invests around 15% of its turnover in R&D and has a portfolio of 1,500 patents worldwide. The Bracco Group deploys an integrated approach to diagnostic imaging, with an offer that encompasses contrast media, its core business where it is one of the world's top players, biomedical equipment from Esaote, one of the world's primary producers of magnetic resonance and ultrasonographic medical equipment, contrast media delivery systems from Acist Medical Systems, a top US company in advanced contrast media injection systems, and medical application software from EBIT-AET and Singapore's Volume Interactions, the leading developer of advanced medical software. Bracco has formed a high-level international research network, whose three centers in Milan, Geneva and Princeton study and develop products for the latest-generation diagnostic techniques, from X-rays and computerized axial tomography to magnetic resonance and echo contrast.

Ultrasound Contrast Agents:

From SIUI Inc.;
'The CTS-310B is designed for the diagnosis of liver, gall, kidney, pancreas, thyroid, breast, uterus, bladder, ovary, etc. It is a versatile ultrasound scanner with both linear array scanning and convex scanning.'
Features:
'Powerful image processing circuit & High quality image
A wide range of probes for selection
Cineloop
Probe frequency conversation option
Computer image communication
Various measuring function
Backlit keyboard'

From SIUI Inc.;
'SIUI's newly developed CTS-485 is a portable ultrasound system with advanced technology. With its powerful features, such as 256 grayscale, cineloop, RS232C interface and broadband high-density, multi-frequency probes, the system is designed for professional applications in cardiology, abdominal, small parts, liver, gallbladder, kidney, obstetrics, gynecology, peripheral vascular, etc. The CTS-485 has passed FDA clearance and CE Marking.'